Navigation Links
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)

SAN DIEGO, Dec. 6, 2016 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, announced today that it entered into collaboration with Takeda Pharmaceutical Company Limited, to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal (GI) related disorders, utilizing Arcturus' wholly-owned therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. The financial terms were not disclosed.

"Given Takeda's long-standing commitment to and expertise in GI disorders, we are confident we have found an ideal partner to accelerate and maximize the potential of our LUNAR and UNA technology platforms toward the development of novel RNA therapeutics for the treatment of NASH," said Dr. Pad Chivukula, CSO & COO of Arcturus Therapeutics, Inc. "This agreement underscores Arcturus' ability to rapidly discover, design and optimize RNA medicines in areas of unmet need." 

About Arcturus Therapeutics, Inc.   

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S., Europe, Japan and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Ultragenyx Pharmaceutical, Inc. For more information, visit

Logo -


To view the original version on PR Newswire, visit:

SOURCE Arcturus Therapeutics
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
2. Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
3. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
4. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
5. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
6. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
7. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
8. Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy
9. Mission Therapeutics Appoints Colin Goddard as Chairman
10. Research Reports Initiation on Healthcare Stocks -- NuVasive, Smith & Nephew, Nxstage Medical, and Cesca Therapeutics
11. Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia
Post Your Comments:
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):